392 trials
Infant Development · Hemiplegia · Constraint Induced Movement Therapy
Primary: CIMT Fidelity — 3.76 score on a scale
Inflammation · Cardiovascular Diseases · Zinc Deficiency
Primary: Effect of Zinc Supplementation on Zinc Levels at 24 Weeks in HIV-infected Subjects — 8.60; 33.50 absolute change (μg/dL) — p=<0.01
Stroke
Primary: Change in Upper Extremity Fugyl-Meyer Score (UEFM) — 2.625; 2.625 change score from baseline to post-test
Menopause
Primary: Effect of CE/BZA (TSEC) on Body Composition — 91.3; 90.6; 45.5; 45.7 Kilograms
Preeclampsia
Primary: Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) — 95; 77 % of maximal cutaneous conductance
Glioblastoma Multiforme · Glioma of Brain
Primary: Maximum Tolerated Dose (MTD) — 600; 70 milligrams
Cerebral Palsy
Primary: Change in Muscle Activity — -0.09 percent change based on mV/mV measures
Environmental Exposure
Primary: Peak Plasma Concentration of 14C-BaP Cmax — 7.07; 1.60 fg [14C]-BaP/mL plasma
Environmental Exposure
Primary: Peak Plasma Concentration Cmax — 2.51; 5.68; 13.8; 8.99 fg [14C]-BaP/mL plasma
Aging
Primary: Tissue Saturation Index (TSI) - Active Leg Muscle — -5.1; -3.1; -8.7; -6.3 % Total Labile Signal
Kabuki Syndrome
Primary: Benton Judgement of Line Orientation — 8.6; 11.6 score on a scale
Environmental Exposure
Primary: Peak Plasma Concentration of 14C-BaP Cmax — 3.69; 1.67; 0.68 fg [14C]-BaP/mL plasma
Sickle Cell Disease · Anti-D Antibodies
Primary: Anti-D Recurrence — 0; 5 Participants
Gastroparesis
Primary: Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index — 2.9; 2.3; 2.2; 2.6…
Malaria, Vivax
Primary: Number of Participants With Serious Adverse Events — 1 Participants